“You may choose to look the other way, but you can never say again that you did not know.”

— William Wilberforce

Front Page » Business » Pharma » Therapeutic Vaccine Market is Big Business
Pharma
Text size:

Therapeutic Vaccine Market is Big Business

vaccines-marketStory Highlights

  • Introduction of the first so-called therapeutic vaccine opened up a new market for vaccine manufacturers.
  • Medical interventions defined as vaccines are protected under a law that shields vaccine manufacturers from legal liability for any adverse reactions that may occur.
  • The global “therapeutic vaccine” market is expected to reach $47.44 billion by 2022.

When the U.S. Food and Drug Administration (FDA) approved the first “therapeutic vaccine,”1 which is defined as a therapy that manipulates the immune system, a whole new market opened up for the vaccine industry. Driven as it is by an increasing worldwide incidence of such chronic diseases as cancer and HIV, the therapeutic vaccine market also includes immunotherapies for addictions, autoimmune diseases, infectious diseases and neurological diseases.2 That’s the big global market with unlimited potential for significant profits.

According to the research firm Market Data Forecast, the scope of that therapeutic vaccine market in North America is expected to rise from $365.79 million in 2015 to a projected $1.399 billion by 2020, with a very impressive compounding annual growth rate (CAGR) of 30.77 percent.3 Globally, Zion Market Research puts the numbers at $10.54 billion in 2016, with an expected rise to $47.44 billion by 2022, for a CAGR of approximately 28.5 per cent from 2017 to 2022.4

“Vaccination” is Not the Same as “Immunotherapy”

The distinction between preventive or prophylactic vaccines and therapeutic vaccines is a critical one. Unlike the original word “vaccination” that described Edward Jenner’s attempt in 1796 to prevent smallpox by injecting healthy humans with cowpox, the word “vaccine” is now being associated with a very different type of pharmaceutical product that attempts to heal a person already sick with a disease.

Departing from traditional vaccines, which are designed to prevent healthy people from getting sick from an infectious disease by exposing them to the lab-altered disease pathogen before they get sick, therapeutic vaccines are intended to treat sick people with an existing infectious or non-infectious disease by manipulating the body’s immune response to make the body return to health.

As explained by Yang et al in an article discussing the human papilloma virus (HPV), prophylactic vaccines are designed to “generate neutralizing antibodies against viral particles [while] therapeutic HPV vaccines are used to stimulate cell-mediated immune responses to specifically target and kill infected cells.”5

It is more than a simple confusion of semantics when most immune therapies are now being referred to as vaccines. There are very specific federal regulatory and product liability laws pertaining to vaccines that don’t apply to any other medical intervention. Specifically, there is “no legal accountability for any corporation or individual who develops, licenses, recommends, promotes, administers or mandates vaccines that injure and kill Americans.”6

Under the National Childhood Vaccine Injury Act (NCVIA) and by a 2011 U.S. Supreme Court ruling, drug companies manufacturing federally licensed and recommended vaccines are effectively completely shielded from legal liability for any harm that may be caused by a vaccine the Centers for Disease Control and Prevention (CDC) recommends for children.7

Optimistic Hopes for 1986 Vaccine Law

In 1982, when U.S. vaccine manufacturers threatened to leave the U.S. with no vaccines for children unless they were protected from vaccine injury lawsuits, Congress began developing legislation that they said would protect the vaccine supply and also provide compensation for vaccine injured children. The historic National Childhood Vaccine Injury Act (NCVIA) of 1986 was groundbreaking in that it formally acknowledged the reality of vaccine injuries and deaths, the need for financial support for the vaccine injured and their families, and the need for vaccine safety and informed consent protections.8

The original law included vaccine safety provisions secured by the co-founders of the non-profit charity National Vaccine Information Center (NVIC), which required pediatricians and other vaccine providers to give parents vaccine benefit and risk information before vaccinating children, to keep written records of the manufacturer’s name and lot numbers for all vaccines given, to keep permanent records of serious health problems following vaccination, and to report vaccine adverse events to the federal Vaccine Adverse Events Reporting System (VAERS) created under the law.

By 2016, nearly $3.6 billion dollars had been given “to vaccine victims for their catastrophic vaccine injuries,” despite the fact that two thirds of applications are denied.9

Reality Far Different From Promises Made

The 1986 law was supposed to provide a more just, less expensive, less traumatic and expedited administrative federal vaccine injury compensation program (VICP) alternative to filing a lawsuit in civil court for vaccine damaged children and their families.

In the words of NVIC co-founder and president Barbara Loe Fisher, who has often described how the promises Congress made to parents of vaccine damaged children have not been kept,:

We were promised that the program would be a non-adversarial, expedited, less traumatic and less expensive administrative alternative to a lawsuit—not an exclusive legal remedy that prohibited all product liability lawsuits against vaccine manufacturers.10

She adds:

We believed that Congress would keep the promises made to parents when it gave partial liability protection to the pharmaceutical industry producing vaccines and the medical trade industry representing pediatricians. We believed that the informing, reporting and recording vaccine safety provisions, which the co-founders of NVIC were specifically responsible for securing into that law, would be enforced.10

Just one example of how the VICP has failed to be implemented properly by the government is outlined in a 2014 report by the Government Accountability Office, which pointed out that most vaccine injury cases filed in the VICP since 1999 have taken more than five years to adjudicate, with one taking more than 14 years to settle. Nearly two-thirds of petitioners who went through the program—whether they received compensation or not—reported they were very dissatisfied with how long the process took.11 The original law put a 240-day deadline for all vaccine injury claims to be processed.12

In addition, two out of three injury claims are turned down for federal compensation and so the majority of vaccine injured children and adults who apply for assistance are left with no financial support to deal with their often catastrophic vaccine injuries. The failure of the 1986 law, together with aggressive lobbying efforts by industry, medical trade and government to eliminate vaccine exemptions and erode informed consent rights, has prompted NVIC and many other consumer groups to call for a return to full civil liability for vaccine manufacturers and those administering vaccines to children and adults.

Financial Incentive to Label Immunotherapies “Vaccines”

With billions of U.S. tax dollars funding the development of hundreds of new experimental vaccines and, in light of the fact that FDA licensing standards having been lowered to allow for fast tracking of those experimental vaccines to market—plus no legal liability regardless of how much harm poorly studied vaccines cause—it is not surprising that those in the business of creating and marketing therapeutic immune therapy products want to call them “vaccines.” 

The name “vaccine” keeps those products under the same civil liability shield umbrella that vaccines enjoy.


References:

1 FDA Approves First Therapeutic Cancer Vaccine. National Cancer Institute May 4, 2010.
2 Global Therapeutic Vaccines Market will reach USD 47.44 Billion by 2022: Zion Market Research. Zion Market Research Mar. 3, 2017.
3 North America Therapeutic Vaccines Market by Disease Type (Autoimmune Disease, Cancer, Neurological Disease, Infectious Disease) and by region – Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021). Market Data Forecast December 2016.
4 
See Footnote 2.
5 
Yang A et al. Perspectives for Therapeutic HPV Vaccine Development. J Biomed Sci. Nov. 4, 2016.
6 
National Vaccine Information Center. Vaccine Injury Compensation: Government’s Broken Social Contract with Parents. NVIC Newsletter Nov. 2, 2015.
7 
NVIC. National Vaccine Information Center Cites “Betrayal” of Consumers by U.S. Supreme Court Giving Total Liability Shield to Big Pharma. BusinessWire Feb. 23, 2011.
8 NVIC. The National Childhood Vaccine Injury Act of 1986. NVIC.org 2017.
9 NVIC. Vaccine Injury Compensation Program (VICP). NVIC.org. 2017.
10 NVIC. Vaccine Injury Compensation: Government’s Broken Social Contract with Parents. NVIC Newsletter Nov. 2, 2015.
11 Government Accountability Office. Report to Chairman, Committee on Oversight and Government Reform, House of Representatives: Vaccine Injury Compensation: Most Claims Took Multiple Years and Many Were Settled Through Negotiations. pp. 9-10 November 2014.
12 Parker CB. Federal Program for Vaccine-Injured Children Is Failing, Stanford Scholar Says. Stanford News July 6, 2015.

3 Responses to Therapeutic Vaccine Market is Big Business

  1. D. Smith Reply

    November 15, 2017 at 10:26 am

    We need to beware of “new” medical things. Immunotherapy is in the infant stage of research and should be looked at much more closely before we start proclaiming it to be the savior of modern medicine.

  2. Alexis Keiser Reply

    November 15, 2017 at 1:08 am

    Yes. I agree with you that manufacturers want to develop more “vaccines” whether or not the particular therapy technically meets the criteria of a vaccine. I also agree that this would save them on the costs of development since vaccines do not undergo the level of testing of other pharmaceuticals. However, I think they are more prone to liability than your piece seems to communicate. For one thing, people who have been injured by traditional vaccine products would likely reject the newer therapies due to the fact that they tamper with the immune system. I am concerned that these products would be uniquely dangerous being derived from inadequate science, poorly tested and likely manufactured with little to no quality control. Additionally, if a “vaccine” is developed for adults it does not fall under the provisions of the 1986 act if it is not approved for use on the childhood vaccination schedule. Lawsuits are proceeding for the adult shingles vaccine and I believe the Fluad vaccine is similarly vulnerable. I mention Fluad intentionally because of the adjuvant used and because it is specifically marketed to people over the age of 65. This vaccine is “adjuvated” (manufacturer’s term) with squalene. I believe squalene adjuvants are particularly likely to promote severe, life-threatening autoimmunity. This is due to the fact that squalene is ubiquitous in the human body AND apparently a strong immune stimulant. The manufacturer’s on-line ad for this product confirms this information, but for obvious reasons does not state the obvious: That their product is likely to turn your body against itself. I suspect squalene sequestered in cells is a good thing, released into tissues it is a very bad thing. Since this product is specifically marketed to those over 65 I think it is a slam dunk for liability if the adjuvant does what I think it does.

    • Erwin Alber Reply

      November 16, 2017 at 8:49 am

      Just as tetanus shots for females in developing countries are in fact contraceptive vaccines, so flu shots for the elderly are in my estimation a form of euthanasia.

      When Ruth Richardson was New Zealand Minister of Health, cynics referred to the free flu shot programme for the elderly she was pushing as “Ruthanasia.”

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>